Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Precision Medicine Rapidly Being Incorporated Into Ovarian Cancer Care

September 18th 2017

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.

Multigene Testing Adds Complexity to Decision Making Process

September 16th 2017

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

Frontline Osimertinib Doubles PFS for EGFR+ NSCLC

September 9th 2017

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Emerging Approaches in Liver Cancer

September 8th 2017

Biomarkers in Liver Cancer

September 8th 2017

Immunotherapy in Liver Cancer

September 8th 2017

Ongoing Clinical Trials in Second-Line HCC

September 8th 2017

Second-Line HCC: Unmet Needs

September 8th 2017

HCC: Evolution of Frontline Treatment

September 8th 2017

Frontline Lenvatinib in HCC: Study 304

September 8th 2017

Unmet Needs in Systemic Therapy for Liver Cancer

September 8th 2017

Initial Treatment Decisions in Liver Cancer

September 8th 2017

Evidence With SIRT in HCC

September 8th 2017

Role of TACE in Liver Cancer

September 8th 2017

Radiofrequency Ablation Vs Resection in HCC

September 8th 2017

HCC and Liver Transplantation

September 8th 2017

Liver Cancer Screening Strategies

September 8th 2017

Comorbidities and Management of HCC

September 8th 2017

Importance of Multidisciplinary Care in Liver Cancer

September 8th 2017

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.